
THE DEEP DATA SOLUTION FOR NOVEL DISCOVERIES IN ONCOLOGY
Shaping a future with individualized cancer therapy
A world in which individual therapeutic treatments exist for every cancer patient – that is Indivumed’s vision. Using unmatched scientific capabilities and high-quality data and tissues all the way through, we chart the molecular reality of solid cancers, exposing how oncological diseases truly function.
By combining proprietary multi-omics and clinical datasets with AI-assisted advanced
analytics, we drive biomarker discovery as well as novel target identification and validation for potential therapies.
DISCOVERIES BASED ON UNIQUE DATA AND SAMPLES
The powerful discovery machine
Utilizing our unique datasets and our powerful discovery and validation platform nRavel®, we drive the discovery of new therapeutic drug targets, the assessment of molecular signaling pathways, and the identification of biomarkers and gene signatures for the stratification of cancer patients.
nRavel® Rx: Target Identification and Validation,
In-silico and In-vitro
Using nRavel’s unique analytical power combining multi-omics data and deep clinical data with matched patient derived tumor models throughout our in-silico and in-vitro discovery workflows, we identify and validate new therapeutic drug targets.
Patient Based
Target Discovery
Through combining multi-omic expression signatures and prognostic data in selected cohorts, we identify targets that are further characterized and subsequently prioritized using nRavel®.

Patient Based
Cellular Models
Once a therapeutic drug target candidate has been successfully validated in-silico, the next step is to validate them in-vitro on 2D and 3D cell models derived from the original cohort used for the in-silico analyses.

nRavel® Dx: Precision Clinical Trial Design
Benefit from our experience and resources.
Biomarker Based
Patient Selection
Utilizing insights from the target discovery process and our clinical and multi-omics database, clinical trial design can be optimized for each investigative drug. Biomarkers based on these insights facilitate patient screening and stratification, and ultimately speed up the recruiting process.

LET’S MOVE PRECISION ONCOLOGY FORWARD
We partner with biotech or pharmaceutical companies as well as academic institutions to enhance R&D activities and launch new discovery programs, providing expertise, capabilities, and insight knowledge throughout the whole development process.
Get in touch
If you want to discuss a collaboration or learn more about our biomarker and target discovery pipeline, please do not hesitate to get in touch. We look forward to hearing from you.